for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Abcam Plc

ABCA.L

Latest Trade

1,282.00GBp

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

1,006.00

 - 

1,523.00

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Latest Developments

Expedeon Signs Deal With Abcam For Sale Of Its Immunology And Proteomics Business

Nov 11 (Reuters) - EXPEDEON AG EXNG.DE::PURCHASE PRICE IS EQUIVALENT TO TWICE EXPEDEON'S CURRENT MARKET CAPITALIZATION OR MORE THAN 9-TIMES 2018 ANNUAL GROUP REVENUE.SIGNS EUR 120 MILLION DEAL WITH ABCAM FOR SALE OF ITS IMMUNOLOGY AND PROTEOMICS BUSINESS.EXPEDEON AG WILL RETAIN APPROXIMATELY 38 % OF ITS ASSETS AT LEVEL OF INDIVIDUAL FINANCIAL STATEMENTS AND 15 % AT LEVEL OF CONSOLIDATED FINANCIAL STATEMENTS.AGREEMENT COVERS SALE AND TRANSFER OF ALL SHARES IN EXPEDEON HOLDINGS LIMITED (CAMBRIDGE, UK), ORGANISED IN THREE DIVISIONS.AGREEMENT IS SUBJECT TO SHAREHOLDER APPROVAL AT AN EXTRAORDINARY MEETING OF EXPEDEON AG TO BE HELD IN HEIDELBERG ON DECEMBER 19TH, 2019.

Abcam To Buy Expedeon's Proteomics And Immunology Business

Nov 11 (Reuters) - Abcam PLC <ABCA.L>::ABCAM PLC SAYS TO ACQUIRE EXPEDEON'S PROTEOMICS AND IMMUNOLOGY BUSINESS.ABCAM PLC SAYS ACQUISITION EXPECTED TO BE ACCRETIVE FROM FIRST FULL YEAR OF OWNERSHIP (FY21).ABCAM -PROPOSED ACQUISITION OF EXPEDEON'S PROTEOMICS AND IMMUNOLOGY BUSINESS FOR A CASH CONSIDERATION OF EUR 120 MILLION ON A CASH FREE / DEBT FREE BASIS.ABCAM PLC SAYS ACQUISITION TO BE FUNDED FROM A DRAWDOWN OF GROUP'S REVOLVING CREDIT FACILITY AND EXISTING CASH RESOURCES.ABCAM PLC SAYS PROPOSED TRANSACTION RESULTS IN ACQUISITION OF SUBSTANTIALLY ALL REVENUES, PROFITS AND ASSETS OF EXPEDEON.ABCAM PLC SAYS ACQUISITION IS EXPECTED TO BE NEUTRAL TO ABCAM'S ADJUSTED EARNINGS IN CURRENT FINANCIAL YEAR (FY20).

Abcam FY Pretax Profit Falls 18.4% To 56.4 Mln Stg

Sept 9 (Reuters) - Abcam PLC <ABCA.L>::FY PRETAX PROFIT FELL 18.4 PERCENT TO 56.4 MILLION STG.FY REVENUE ROSE 11.4 PERCENT TO 259.9 MILLION STG.PROPOSED FINAL DIVIDEND OF 8.58P (2017/18: 8.58P).NEW FIVE-YEAR PLAN TARGETING REVENUE OF £450-500M IN 2023/24.2023/24 ADJUSTED OPERATING PROFIT MARGIN EXPECTED TO REACH LOW-THIRTIES %.TOTAL CAPITAL EXPENDITURE OVER 2023/24 EXPECTED TO BE £175-225M.2019/20 TRADING PERFORMANCE YEAR TO DATE IS IN LINE WITH BOARD'S EXPECTATIONS.FOR 2019/20, TARGETING TOTAL REVENUE OF £288-294M, EQUIVALENT TO CONSTANT CURRENCY REVENUE GROWTH OF 9-11%.FOR 2019/20, TOTAL ESTIMATED CAPITAL EXPENDITURE IN REGION OF £30-50M, INCLUDING IT TRANSFORMATION.FOR 2019/20, ANTICIPATED ADJUSTED OPERATING PROFIT MARGIN OF 25-28%, DEPENDENT ON PHASING OF STRATEGIC INVESTMENTS.FOR 2019/20, SEES EQUIVALENT ADJUSTED EBITDA MARGIN OF 32-35%.

Abcam Says CFO Gavin Wood To Step Down

July 22 (Reuters) - Abcam PLC <ABCA.L>::ABCAM PLC - ITS CHIEF FINANCIAL OFFICER, GAVIN WOOD, HAS TODAY SERVED NOTICE OF HIS INTENTION TO STEP DOWN.ABCAM PLC - SEARCH FOR WOOD'S SUCCESSOR WILL COMMENCE IMMEDIATELY.

Abcam Sees FY Rev, Gross Margin To Be Higher Than Last Yr

July 22 (Reuters) - Abcam PLC <ABCA.L>::FULL YEAR TRADING UPDATE.EXPECTS TO REPORT FY TOTAL REVENUE OF £259.9 MILLION (2017/18: £233.2 MILLION).SEES FY GROSS MARGIN TO BE AHEAD OF LAST YEAR AND ADJUSTED EBITDA MARGIN TO BE IN LINE WITH BOARD'S EXPECTATIONS.CURRENTLY REVIEWING ITS PLANS FOR NEXT FIVE YEARS TO 2023/24.

Abcam PLC Announces Acquisition Of Cell Lines And Lysates Portfolio

July 16 (Reuters) - Abcam PLC <ABCA.L>::ABCAM PLC - ACQUISITION OF CELL LINES AND LYSATES PORTFOLIO.ABCAM - FINANCIAL TERMS OF DEAL HAVE NOT BEEN DISCLOSED AND ARE EXPECTED TO HAVE A MINIMAL IMPACT ON REVENUE AND EARNINGS IN CURRENT FINANCIAL YEAR.

Entities Affiliated With Standard Life Aberdeen Disclose 5.08 Pct Stake In Abcam

March 12 (Reuters) - Abcam PLC <ABCA.L>::ENTITITES AFFILIATED WITH STANDARD LIFE ABERDEEN DISCLOSE 5.08 PERCENT STAKE IN ABCAM PLC AS OF MAR. 8 - FILING.

Abcam Announces Acquisition Of Calico Biolabs

Jan 28 (Reuters) - Abcam PLC <ABCA.L>::ACQUISITION OF CALICO BIOLABS.FINANCIAL TERMS OF TRANSACTION HAVE NOT BEEN DISCLOSED.TRANSACTION EXPECTED TO HAVE A MINIMAL IMPACT ON REVENUE AND EARNINGS FOR FY2019.

Abcam Says Implementing Contingency Plans Ahead Of Potential 'No-Deal' Brexit

Jan 8 (Reuters) - Abcam PLC <ABCA.L>::DOUBLE-DIGIT GROWTH DELIVERED IN H1; ON TRACK TO ACHIEVE FY19 GOALS.GROUP EXPECTS TO REPORT TOTAL REVENUE GROWTH FOR FIRST HALF OF APPROXIMATELY 11% ON A REPORTED BASIS.EXPECTS TO REPORT GROSS MARGIN FOR FIRST HALF MODESTLY AHEAD OF LAST YEAR, IN LINE WITH BOARD'S EXPECTATIONS.GROUP HAS BEGUN IMPLEMENTING CONTINGENCY PLANS AHEAD OF A POTENTIAL 'NO-DEAL' BREXIT IN ORDER TO MINIMISE RISK OF DISRUPTION TO CUSTOMERS.

Abcam Says FY Pretax Profit Rose 33.1 Pct To 69.1 Mln Stg

Sept 10 (Reuters) - Abcam PLC <ABCA.L>::FY PRETAX PROFIT ROSE 33.1 PERCENT TO 69.1 MILLION STG.FY REVENUE ROSE 7.4 PERCENT TO 233.2 MILLION STG.LONG-TERM MARKET OUTLOOK REMAINS POSITIVE; GOOD MOMENTUM ACROSS BUSINESS.PROPOSED FINAL DIVIDEND OF 8.58P (2016/17: 7.36P) FOR FY.AMBITION TO MAINTAIN REVENUE GROWTH AT LOW DOUBLE-DIGIT RATES OVER MEDIUM-TERM.ANTICIPATE 2018/19 ADJUSTED EBITDA MARGIN OF ABOUT 36 PCT AS A RESULT OF INCREASED INVESTMENT IN STRATEGIC INITIATIVES.EXPECT TOTAL CONSTANT CURRENCY REVENUE GROWTH FOR 2018/19 OF ABOUT 11 PCT.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up